Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Anteris Technologies Global Corp. Common Stock (AVR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: AVR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $16.5
1 Year Target Price $16.5
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.11% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 178.87M USD | Price to earnings Ratio - | 1Y Target Price 16.5 |
Price to earnings Ratio - | 1Y Target Price 16.5 | ||
Volume (30-day avg) 4 | Beta 0.34 | 52 Weeks Range 2.34 - 8.79 | Updated Date 10/17/2025 |
52 Weeks Range 2.34 - 8.79 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3379.29% |
Management Effectiveness
Return on Assets (TTM) -184.05% | Return on Equity (TTM) -618.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 133044428 | Price to Sales(TTM) 72.15 |
Enterprise Value 133044428 | Price to Sales(TTM) 72.15 | ||
Enterprise Value to Revenue 53.67 | Enterprise Value to EBITDA - | Shares Outstanding 36062370 | Shares Floating 30362352 |
Shares Outstanding 36062370 | Shares Floating 30362352 | ||
Percent Insiders 0.21 | Percent Institutions 47.58 |
Upturn AI SWOT
Anteris Technologies Global Corp. Common Stock
Company Overview
History and Background
Anteris Technologies (formerly Admedus) is a structural heart company focused on developing and commercializing DurAVRu2122, a novel single-piece heart valve designed for rapid implant and long-term durability, addressing critical unmet needs in the treatment of aortic stenosis.
Core Business Areas
- DurAVRu2122 Aortic Valve: Development and clinical trials for the DurAVRu2122 aortic valve, a single-piece valve aimed at reducing calcification and structural valve deterioration. This is the main business area currently.
Leadership and Structure
Wayne Roffe serves as the CFO. The company is structured around research & development, clinical trials, and regulatory approvals for DurAVRu2122.
Top Products and Market Share
Key Offerings
- DurAVRu2122 Aortic Valve: The DurAVRu2122 aortic valve is Anteris's primary product under development. It's designed to be a single-piece valve intended to minimize structural valve deterioration. It is in the clinical trial phase. Competitors include Edwards Lifesciences (EW) and Medtronic (MDT), which have established bioprosthetic valves and transcatheter aortic valve replacement (TAVR) systems. Market share data is not yet applicable as the product is not commercially available.
Market Dynamics
Industry Overview
The structural heart market is experiencing significant growth, driven by an aging population and advancements in minimally invasive valve replacement technologies. TAVR, in particular, is a rapidly expanding segment.
Positioning
Anteris aims to differentiate itself with the DurAVRu2122 valve's potential for improved durability and reduced calcification, addressing limitations of existing bioprosthetic valves.
Total Addressable Market (TAM)
The global heart valve market is estimated to be in the billions of dollars. The structural heart market, which Anteris targets, is expected to reach $12.5 billion by 2029. Anteris is positioned to capture a portion of this market with its DurAVRu2122 valve if it proves superior to existing offerings. The current market cap for Anteris is roughly $0.5 billion which shows their position in the market.
Upturn SWOT Analysis
Strengths
- Novel valve design with potential for improved durability
- Focus on unmet needs in aortic valve replacement
- Early-stage clinical trial data showing promising results
Weaknesses
- Product not yet commercially available
- High dependence on successful clinical trial outcomes
- Limited financial resources compared to larger competitors
Opportunities
- Expanding TAVR market
- Potential for partnerships with larger medical device companies
- Positive clinical trial data leading to accelerated regulatory approval
Threats
- Competition from established players like Edwards Lifesciences and Medtronic
- Unsuccessful clinical trial outcomes
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- Edwards Lifesciences (EW)
- Medtronic (MDT)
- Abbott (ABT)
Competitive Landscape
Anteris is an emerging player challenging the dominance of larger, established companies. Its competitive advantage lies in the DurAVRu2122 valve's novel design and potential for improved durability. However, it faces significant challenges in competing with the established market presence and resources of its competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal as the company focuses on R&D and clinical trials.
Future Projections: Future growth depends heavily on successful commercialization of DurAVRu2122. Analyst estimates vary widely, but assume a large market opportunity assuming approvals are successful.
Recent Initiatives: Anteris is currently enrolling patients in the pivotal trial for DurAVRu2122.
Summary
Anteris Technologies is a high-risk, high-reward company. Its success hinges on the DurAVRu2122 valve's successful clinical trials and commercialization. While the potential market is large and the technology promising, the company faces significant competition and financial challenges. The market will be closely watching the progress of the DurAVRu2122 valve pivotal trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anteris Technologies Global Corp. Common Stock
Exchange NASDAQ | Headquaters Toowong, QLD, Australia | ||
IPO Launch date 2024-12-13 | Vice Chairman & CEO Mr. Wayne Geoffrey Paterson | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 136 | Website https://anteristech.com |
Full time employees 136 | Website https://anteristech.com | ||
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.